Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 119.8
(-0.33%)
SAR 119.8
(-0.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 65.82 Million SAR | 10.72% |
| 2022 | 59.45 Million SAR | -10.31% |
| 2021 | 66.28 Million SAR | -8.97% |
| 2020 | 72.81 Million SAR | 34.71% |
| 2019 | 54.05 Million SAR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 21.8 Million SAR | 132.72% |
| 2024 Q1 | 9.37 Million SAR | -61.18% |
| 2023 Q4 | 24.13 Million SAR | 0.0% |
| 2023 Q3 | 24.13 Million SAR | 33.78% |
| 2023 FY | 65.82 Million SAR | 10.72% |
| 2023 Q2 | 18.04 Million SAR | 3734.43% |
| 2023 Q1 | -496.48 Thousand SAR | -102.38% |
| 2022 Q1 | 8.83 Million SAR | 0.0% |
| 2022 FY | 59.45 Million SAR | -10.31% |
| 2022 Q4 | 20.88 Million SAR | 0.0% |
| 2022 Q2 | 20.24 Million SAR | 129.03% |
| 2022 Q3 | 20.88 Million SAR | 3.19% |
| 2021 FY | 66.28 Million SAR | -8.97% |
| 2020 FY | 72.81 Million SAR | 34.71% |
| 2019 FY | 54.05 Million SAR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 329.22 Million SAR | 80.005% |
| Nahdi Medical Company | 892.61 Million SAR | 92.625% |
| Al-Razi Medical Co. | 685.96 Thousand SAR | -9496.271% |
| Almujtama Alraida Medical Co. | 11.39 Million SAR | -477.79% |